Budget 2022: PHARMAC boost leaves patients cold: 'it won't be enough'

19 May 2022 - PHARMAC has had its biggest ever funding boost, but some New Zealanders fear it still won’t ...

Read more →

Bonesupport receives market authorisation for Cerement G in the US

18 May 2022 - BoneSupport today announced that the company has received market authorisation from the U.S. FDA, for the ...

Read more →

PTC Therapeutics receives positive CHMP opinion for Upstaza for the treatment of AADC deficiency

20 May 2022 - First ever gene therapy directly administered into the brain. ...

Read more →

FDA approves azacitidine for newly diagnosed juvenile myelomonocytic leukaemia

20 May 2022 - Today the FDA approved azacitidine (Vidaza, Celgene) for paediatric patients with newly diagnosed juvenile myelomonocytic leukaemia. ...

Read more →

People dying of COVID while life-saving drugs go unused, doctors say

21 May 2022 - Top doctors have warned that vulnerable patients who test positive to COVID-19 are missing out on ...

Read more →

CHMP recommends approval of Xenpozyme (olipudase alfa), the first and only treatment for ASMD

20 May 2022 - Recommendation based on positive results from two clinical trials in which Xenpozyme provided improvement across multiple non-CNS ...

Read more →

Karyopharm and Menarini Group receive positive CHMP opinion for Nexpovio (selinexor) for the treatment of patients with refractory multiple myeloma

20 May 2022 - European Commission decision anticipated within approximately 60 days. ...

Read more →

Novartis Cosentyx (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions

20 May 2022 - Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in paediatric enthesitis-related arthritis ...

Read more →

FDA approves first treatment for eosinophilic esophagitis, a chronic immune disorder

20 May 2022 - Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab) to treat eosinophilic esophagitis in adults and ...

Read more →

CHMP recommends approval of Lilly and Incyte's Olumiant (baricitinib) as the first and only centrally authorised treatment for adults with severe alopecia areata

20 May 2022 - Eli Lilly and Incyte announced today that the EMA's CHMP has issued a positive opinion for ...

Read more →

AbbVie submits new drug application to U.S. FDA for investigational ABBV-951 (foscarbidopa/foslevodopa) for the treatment of advanced Parkinson's disease

20 May 2022 - Submission is supported by Phase 3 study that demonstrated patients had significant increases in hours of ...

Read more →

Highlights from the 16-19 May 2022 CHMP meeting

20 May 2022 - The EMA’s human medicines committee (CHMP) recommended nine medicines for approval at its May 2022 meeting. ...

Read more →

Lumasiran for treating primary hyperoxaluria type 1

20 May 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using lumasiran ...

Read more →

Viatris and Biocon Biologics launch Abevmy (bevacizumab), their third oncology siosimilar, in Canada

19 May 2022 - Viatris and Biocon Biologics announced today that Abevmy (bevacizumab) is now available in Canada.  ...

Read more →

Mirati Therapeutics submits marketing authorisation application to the European Medicines Agency for investigational adagrasib as a treatment for previously treated KRASG12C mutated non-small-cell lung cancer

19 May 2022 - Submission follows the U.S. FDA acceptance of the adagrasib new drug application for the same indication ...

Read more →

NeuroMetrix reports that Quell wearable neuromodulation device has received FDA de novo authorisation as first non-pharmacological treatment for fibromyalgia

19 May 2022 - NeuroMetrix today announced U.S. FDAde novo authorisation to market the Quell neuromodulation device as an ...

Read more →